Treatment and prevention strategies to combat pediatric pneumococcal meningitis

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 5, 2005, Pages 739-750

  McIntosh, E David G ^a,b  

^a PFIZER INC   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antibiotics; Immunization; Pathogenesis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BACTERIAL DNA; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CLINDAMYCIN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C9; DEXAMETHASONE; FAS LIGAND; GATIFLOXACIN; INTERLEUKIN 8; LIPOTEICHOIC ACID; MELATONIN; MEROPENEM; MOXIFLOXACIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENICILLIN G; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VANCOMYCIN;

ADOLESCENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM DETECTION; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDEMIC; GHANA; HEARING LOSS; HUMAN; INCIDENCE; INFANT; LUMBAR PUNCTURE; MINIMUM INHIBITORY CONCENTRATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CHILD; HUMANS; MENINGITIS, PNEUMOCOCCAL; PRACTICE GUIDELINES; SEROTYPING;

EID: 27544465104     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.5.739     Document Type: Review

References (110)

1. McMaster P, McIntrye P, Gilmour R, Gilbert L, Kakakios A, Mellis C. The emergence of resistant pneumococcal meningitis - implications for empiric therapy. Arch. Dis. Child. 87, 207-210 (2002).
2. Kaplan S. Management of pneumococcal meningitis. Pediatr. Infect. Dis. J. 21, 589-591 (2002).
3. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39, 1267-1284 (2004).
4. Black S, Shinefield H, Fireman B et al., and the Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19, 187-195 (2000).
5. Whitney CG, Farley MM, Hadler J et al., for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746 (2003).
6. de Andrade AL, Pimenta FC, Laval CA, de Andrade JG, Guerra ML, Brandileone MC. Invasive pneumococcal infection in a healthy infant caused by two different serotypes. J. Clin. Microbiol. 42, 2345-2346 (2004).
7. Almasanu BP, Owensby JR, Pavlakis SG, Edwards JH. Spinal cord infarction in meningitis: polygenic risk factors. Pediatr. Neurol. 32, 124-126 (2005).
8. Chin RF, Neville BG, Scott RC. Meningitis is a common cause of convulsive status epilepticus with fever. Arch. Dis. Child. 90, 66-69 (2005).
9. Pong A, James HE, Senac MO Jr, Hartl K. Pneumococcal infection of the cavum septi pellucidi and cavum vergae in a pediatric patient. Pediatr. Infect. Dis. J. 22, 1014-1017 (2003).
10. Enders A, Pannicke U, Berner R et al. Two siblings with lethal pneumococcal meningitis in a family with a mutation in interleukin-1 receptor-associated kinase 4. J. Pediatr. 145, 698-700 (2004).
11. EPIBAC. Surveillance des méningites à H. influenzae, N. meningitidis, L. monocytogenes, S. pneumoniae par le réseau 1987-1993.
12. Eriksson M, Henriques B, Ekdahl K. Epidemiology of pneumococcal infections in Swedish children. Acta Paediatr. 89(Suppl. 435), 35-39 (2000).
13. Bernaola Iturbe E, Aristegui Fernandez J, Herranz Aguirre M, Garcia Calvo C, Fernandez Perez C; Grupo de Estudio de Enfermedad Invasora Neumococica en el Pais Vasco-Navarra. Study of the incidence of invasive pneumococcal disease in neonates and children aged less than 5 years in the Basque country and Navarre (Spain). An. Esp. Pediatr. 57, 301-309 (2002).
14. Rendi-Wagner P, Georgopoulos A, Kundi M et al. Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria. J. Antimicrob. Chemother. 53, 826-831 (2004).
15. Kaltoft MS, Madsen J, Konradsen HB. An age-adjusted comparison of the coverage by the 7-valent pneumococcal conjugate vaccine of carried and invasive isolates from Danish children aged 12 to 83 months. The 4th International Symposium on Pneumococci and Pneumococcal Disease (ISPPD-4). Helsinki, Finland (2004).
16. King BA, Richmond P. Pneumococcal meningitis in Western Australian children: epidemiology, microbiology and outcome. J. Paediatr. Child Health 40, 611-615 (2004).
17. Kim JS, Jang YT, Mik JD et al. Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. Vaccine 22, 3952-3962 (2004).
18. Levine M, Rosanna L, Levine O et al. Epidemiology of invasive pneumococcal infections in infants and young children in metropolitan Santiago, Chile, a newly industrializing country. Pediatr. Infect. Dis. J. 17, 287-293 (1998).
19. Mar ID, Denis F, Cadoz M. Epidemiologic features of pneumococcal meningitis in Africa. Clinical and serotypical aspects. Pathol. Biol. 27, 543-548 (1979).
20. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990: ethnic differences and opportunities for prevention. J. Infect. Dis. 170, 368-376 (1994).
21. O'Dempsey TJ, McArdle TF, Lloyd-Evans N et al. Pneumococcal disease among children in a rural area of west Africa. Pediatr. Infect. Dis. J. 15, 431-437 (1996).
22. Ispahani P, Slack RC, Donald FE, Weston VC, Rutter N. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Arch. Dis. Child. 89, 757-762 (2004).
23. Wandi F, Kiagi G, Duke T. Long-term outcome for children with bacterial meningitis in rural Papua New Guinea. J. Trop. Pediatr. 51, 51-53 (2005).
24. D'Ancona F, Salmaso S, Barale A et al. Italian PNC-Euro Working Group. Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine 23, 2494-2500 (2005).
25. Freeman HR, Mai NT, Diep TS, Parry C, Hien TT, Farrar JJ. The role of polymerase chain reaction in the diagnosis of bacterial meningitis in Vietnam. Ann. Trop. Med. Parasitol. 98, 65-70 (2004).
26. Black S, Shinefield H, Baxter R et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J. 23, 485-489 (2004).
27. Ostergaard C, Brandt C, Konradsen HB, Sameulsson S. Differences in survival, brain damage, and cerebrospinal fluid cytokine kinetics due to meningitis caused by 3 different Streptococcus pneumoniae serotypes: evaluation in humans and in 2 experimental models. J. Infect. Dis. 190, 1212-1220 (2004).
28. Venetz I, Schopler K, Mühlemann K and the Swiss Pneumococcal Study Group. Pediatric, invasive pneumococcal disease in Switzerland, 1985-1994. Int. J. Epidemiol. 27, 1101-1104 (1998).
29. Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect. Dis. 4, 21 (2004).
30. Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J. Infect. Dis. 190, 1661-1669 (2004).
31. Kastenbauer S, Klein M, Koedel U, Pfister HW. Reactive nitrogen species contribute to blood-labyrinth barrier disruption in suppurative labyrinthitis complicating experimental pneumococcal meningitis in the rat. Brain Res. 904, 208-217 (2001).
32. van Ginkel FW, McGhee JR, Watt JM, Campos-Torres A, Parish LA, Briles DE. Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc. Natl Acad. Sci. USA 100, 14363-14367 (2003).
33. de Andrade AL, Pimenta FC, Brandileone MC et al. Genetic relationship between Streptococcus pneumoniae isolates from nasopharyngeal and cerebrospinal fluid of two infants with pneumococcal meningitis. J. Clin. Microbiol. 41, 3970-3972 (2003).
34. Hirst RA, Gosai B, Rutman A, Andrew PW, O'Callaghan C. Streptococcus pneumoniae damages the ciliated ependyma of the brain during meningitis. Infect. Immun. 71, 6095-6100 (2003).
35. Kastenbauer S, Koedel U, Weih F, Ziegler-Heitbrock L, Pfister HW. Protective role of NF-κB1 (p50) in experimental pneumococcal meningitis. Eur. J. Pharmacol. 498, 315-318 (2004).
36. Paul R, Winkler F, Bayerlein I, Popp B, Pfister HW, Koedel U. Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis. J. Infect. Dis. 191, 776-782 (2005).
37. Zwijnenburg PJ, de Bie HM, Roord JJ, van der Poll T, van Furth AM. Chemotactic activity of CXCL5 in cerebrospinal fluid of children with bacterial meningitis. J. Neuroimmunol. 145, 148-153 (2003).
38. Koedel U, Rupprecht T, Angele B et al. MyD88 is required for mounting a robust host immune response to Streptococcus pneumoniae in the CNS. Brain 127, 1437-1445 (2004).
39. Wellmer A, von Mering M, Spreer A et al. Experimental pneumococcal meningitis: impaired clearance of bacteria from the blood due to increased apoptosis in the spleen in Bcl-2-deficient mice. Infect. Immun. 72, 3113-3119 (2004).
40. Koedel U, Paul R, Winkler F, Kastenbauer S, Huang PL, Pfister HW. Lack of endothelial nitric oxide synthase aggravates murine pneumococcal meningitis. J. Neuropathol. Exp. Neurol. 60, 1041-1050 (2001).
41. Paul R, Angele B, Sporer B, Pfister HW, Koedel U. Inflammatory response during bacterial meningitis is unchanged in Fas- and Fas ligand-deficient mice. J. Neuroimmunol. 152, 78-82 (2004).
42. Braun JS, Novak R, Murray PJ et al. Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J. Infect. Dis. 184, 1300-1309 (2001).
43. 2 mediate brain cell apoptosis during meningitis. J. Clin. Invest. 109, 19-27 (2002).
44. Bermpohl D, Halle A, Freyer D et al. Bacterial programmed cell death of cerebral endothelial cells involves dual death pathways. J. Clin. Invest. 115, 1607-1615 (2005).
45. Koedel U, Angele B, Rupprecht T et al. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J. Immunol. 170, 438-444 (2003).
46. Nau R, Gerber J, Bunkowski S, Bruck W. Axonal injury, a neglected cause of CNS damage in bacterial meningitis. Neurology 62, 509-511 (2004).
47. Mitchell L, Smith SH, Braun JS, Herzog KH, Weber JR, Tuomanen EI. Dual phases of apoptosis in pneumococcal meningitis. J. Infect. Dis. 190, 2039-2046 (2004).
48. Gerber J, Bottcher T, Hahn M, Siemer A, Bunkowski S, Nau R. Increased mortality and spatial memory deficits in TNF-α deficient mice in ceftriaxone-treated experimental pneumococcal meningitis. Neurobiol. Dis. 16, 133-138 (2004).
49. Klein M, Koedel U, Pfister HW, Kastenbaur S. Morphological correlates of acute and permanent hearing loss during experimental pneumococcal meningitis. Brain Pathol. 12, 123-132 (2003).
50. Li L, Shui QX Li X. Neuroprotective effects of brain-derived neurotrophic factor (BDNF) on hearing in experimental pneumococcal meningitis. J. Child Neurol. 20, 51-56 (2005).
51. Bifrare YD, Kummer J, Joss P. Tauber MG, Leib SL. Brain-derived neurotophic factor protects against multiple forms of brain injury in bacterial meningitis. J. Infect. Dis. 191, 40-45 (2005).
52. Gerber J, Lotz M, Ebert S et al. Melatonin is neuroprotective in experimental Streptococcus pneumoniae meningitis. J. Infect. Dis. 191, 783-790 (2005).
53. Brandt CT, Lundgren JD, Lund SP et al. Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects fats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis. Infect. Immun. 72, 4647-4653 (2004).
54. Meli DN, Christen S, Leib SL. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J. Infect. Dis. 187, 1411-1415 (2003).
55. Meli DN, Loeffler JM, Baumann P et al. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-α converting enzyme attenuates seizures and injury of the cerebral cortex. J. Neuroimmunol. 151, 6-11 (2004).
56. Klein M, Koedel U, Pfister HW, Kastenbauer S. Meningitis-associated hearing loss: protection by adjunctive anti-oxidant therapy. Ann. Neurol. 54, 451-458 (2003).
57. Braun JS, Novak R, Herzog K-H, Bodner SM, Cleveland JL, Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nature Med. 5, 298-302 (1999).
58. Bottcher T, Ren H, Goiny M et al. Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone. J. Neurochem. 91, 1450-1460 (2004).
59. Spreer A, Kerstan H, Bottcher T et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison with ceftriaxone. Antimicrob. Agents Chemother. 47, 2649-2654 (2003).
60. Olivier C, Cohen R, Begué P. Floret D. Bacteriologic outcome of children with cefotaxime- or ceftriaxone-susceptible and -nonsusceptible Streptococcus pneumoniae meningitis. Pediatr. Infect. Dis. J. 1015-1017 (2000).
61. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J. Clin. Microbiol. 39, 1553-1558 (2001).
62. Kearns AM, Graham C, Burdess D, Heatherington J, Freeman R. Rapid real-time PCR for determination of penicillin susceptibility in pneumococcal meningitis, including culture-negative cases. J. Clin. Microbiol. 40, 682-684 (2002).
63. van Haeften R, Palladino S, Kay I, Kiel T, Heath C, Waterer GW. A quantitative LightCycler PCR to detect Streptococcus pneumoniae in blood and CSF. Diagn. Microbiol. Infect. Dis. 47, 407-414 (2003).
64. Sidikou F, Djibo S, Taha MK et al. Polymerase chain reaction assay and bacterial meningitis surveillance in remote areas, Niger. Emerg. Infect. Dis. 9, 1486-1488 (2003).
65. Rai GP, Zachariah K, Sharma R, Phadake S, Belapurkar KM. Development of a sandwich-dot enzyme linked immunosorbent assay for Streptococcus pneumoniae antigen detection in cerebrospinal fluid. Comp. Immunol. Microbiol. Infect. Dis. 27, 217-223 (2004).
66. Samra Z, Shmeuly H, Nahum E, Paghis D, Ben-Ari J. Use of the NOW Streptococcus pneumoniae urinary antigen test in cerebrospinal fluid for rapid diagnosis of pneumococcal meningitis. Diagn. Microbiol. Infect. Dis. 45, 237-240 (2003).
67. Kanungo B, Bhaskar M, Kumar A, Badrinath S, Rajalakshmi B. Detection of pneumolysin in cerebrospinal fluid for rapid diagnosis of pneumococcal meningitis. Indian J. Med. Res. 119, 75-78 (2004).
68. Requejo HIZ, das Gragu M, Alkmin A, Landgraf IM. Immunodiagnosis of pneumococcal meningitis using dot-enzyme-linked immunosorbent assay. J. Trop. Pediatr. 47, 288-290 (2001).
69. Marchandin H, Ventura V, Alonson JM, Van de Perre P. Mixed bacterial meningitis due to Streptococcus pneumoniae and Neisseria meningitidis in an 18-month-old child. J. Clin. Microbiol. 43, 1477-1479 (2005).
70. Grenon S, von Specht M, Corso A, Pace J, Regueira M. Distribution of serotypes and antibiotic susceptibility patterns of Streptococcus pneumoniae strains isolated from children in Misiones, Argentina. Enferm. Infecc. Microbiol. Clin. 23, 10-14 (2005).
71. Buxmann H, Soerensen J, Koehl U et al. Meningitis due to multiple-resistant penicillin- and cefotaxime-intermediate Streptococcus pneumoniae in a German child after bone marrow transplantation. Infection 31, 425-427 (2003).
72. Fernandez A, Cabelos C, Tubau F et al. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis. J. Antimicrob. Chemother. 55, 78-83 (2005).
73. Cabellos C, Fernandez A, Maiques JM et al. Experimental study of LY-333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 47, 1907-1911 (2003).
74. Cottagnoud P, Pfister M, Acosta F et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 48, 3928-3933 (2004).
75. Kim SW, Jin JH, Kang SJ et al. Therapeutic efficacy of meropenem for treatment of experimental penicillin-resistant pneumococcal meningitis. J. Korean Med. Sci. 19, 21-26 (2004).
76. Cottagnoud P, Cottagnoud M, Acosta F et al. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 22, 656-662 (2003).
77. Flatz L, Cottagnoud M, Kuhn F, Entenza J, Stucki A, Cottagnoud P. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduced levofloxacin-induced resistance in penicillin-resistant pneumococci. J. Antimicrob. Chemother. 53, 305-310 (2004).
78. Kuhn F, Cottagnoud M, Acosta F, Flatz L, Entenza J, Cottagnoud P. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. Antimicrob. Agents Chemother. 47, 2487-2491 (2003).
79. Domenech A, Cabellos C, Ribes S et al. Experimental study of clinafloxacin alone and in combination in the treatment of ciprofloxacin-susceptible and -resistant pneumococcal meningitis. Microb. Drug Resist. Mech. Epidemiol. Dis. 9(Suppl. 1), S53-S59 (2003).
80. Lee H, Song JH, Kim SW et al. Evaluation of a triple-drug combination for treatment of experimental multi-drug resistant pneumococcal meningitis. Int. J. Antimicrob. Agents 23, 307-310 (2004).
81. Buckingham SC, McCullers JA, Luján-Zilbermann J, Knapp KM, Orman KL, English BK. Pneumococcal meningitis in children: relationship of antibiotic resistance to clinical characteristics and outcomes. Pediatr. Infect. Dis. J. 20, 837-843 (2001).
82. Kellner JD, Scheifele DW, Halperin SA et al., Canadian Paediatric Society/Centre for Infectious Disease Prevention and Control Immunization Monitoring Program. Outcome of penicillin-nonsuceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatr. Infect. Dis. J. 21, 903-910 (2002).
83. Hernandez M, Mejia GI, Trujillo H, Robledo J. Effectiveness of the antibiotics chloramphenicol and rifampicin in the treatment of Streptococcus pneumoniae-induced meningitis and systemic infections. Biomedica 23, 456-461 (2003).
84. Duke T, Michael A, Mokela D, Wal T, Reeder J. Chloramphenicol of ceftriaxone, or both, as treatment for meningitis in developing countries? Arch. Dis. Child. 88, 536-539 (2003).
85. McIntyre PB, Macintyre CR, Gilmour R, Wang H. A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis. Arch. Dis. Child. 90, 391-396 (2005).
86. de Gans J, van de Beek D, for the European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med. 347, 1456-1549 (2002).
87. Lutsar I, Friedland IR, Jafri HS et al. Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. J. Antimicrob. Chemother. 52, 651-655 (2003).
88. Leib SL, Heimgartner C, Bifrare YD, Loeffler JM, Taauber MG. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr. Res. 54, 353-357 (2003).
89. Pelton SI, Yogev R. Improving the outcome of pneumococcal meningitis. Arch. Dis. Child. 90, 333-334 (2005).
90. Angstwurm K, Hanisch UK, Gassemi T et al. Tyrosine kinase inhibition reduces inflammation in the acute stage of experimental pneumococcal meningitis. Infect. Immun. 72, 3294-3298 (2004).
91. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20, 1105-1107 (2001).
92. Verhaegen J, Vandecasteele SJ, Vandeven J, Verbiest N, Lagrou K, Peetermans WE. Antibiotic susceptibility and serotype distribution of 240 Streptococcus pneumoniae causing meningitis in Belgium 1997-2000. Acta Clin. Belg. 58, 19-26 (2003).
93. Casado Flores J, Fenoll A, Aristegui Fernandez J et al., Group para el Estudio de la Meningitis Neumococica. Pneumococcal meningitis in Spanish children: incidence, serotypes and antibiotic resistance. An. Esp. Pediatr. 57, 295-300 (2002).
94. Ubukata K, Chiba N, Hasegawa K, Kobayashi R, Iwata S, Sunakawa K. Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob. Agents Chemother. 48, 1488-1494 (2004).
95. Reis JN, Cordeiro SM, Coppola SJ et al. Population-based survey of antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from meningitis patients in Salvador, Brazil. J. Clin. Microbiol. 40, 275-277 (2002).
96. Brandileone M-CC, Sgambatti de Andrade A-LS, Di Fabio J-L, Guerra M-LLS, Austrian R. Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. J. Infect. Dis. 187, 1206-1212 (2003).
97. Saha SK, Baqui AH, Darmstadt GL et al. Comparison of antibiotic resistance and serotype composition of carriage and invasive pneumococci among Bangladeshi children: implications for treatment policy and vaccine formulation. J. Clin. Microbiol. 41, 5582-5587 (2003).
98. Leimkugel J, Forgor AA, Gagneux S et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in Northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J. Infect. Dis. 192, 192-199 (2005).
99. Reefhuis J, Honein MA, Whitney CG et al. Risk of bacterial meningitis in children with cochlear implants. N. Engl. J. Med. 349, 435-445 (2003).
100. Rose M, Hey C, Kujumdshiev S, Gall V, Schubert R, Zielen S. Immunogenicity of pneumococcal vaccination of patients with cochlear implants. J. Infect. Dis. 190, 551-557 (2004).
101. Antin JH, Guinan EC, Avigan D et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 11, 213-222 (2005).
102. de Arístegui Fernández J, Cos Arregui B, Zurimendi Carril A et al. Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months. Vaccine 23, 1917-1922 (2005).
103. Esposito S, Pugni L, Bosis S et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 23, 1703-1708 (2005).
104. Kayhty H, Ahman H, Eriksson K, Sorberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J. 24, 108-114 (2005).
105. Tichmann-Schumann I, Soemantri P, Behre U et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 24, 70-77 (2005).
106. Cutts FT, Zaman SM, Enwere G et al., and the Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365, 1139-1146 (2005).
107. Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr. Infect. Dis. J. 23, 732-738 (2004).
108. Frazao N, Brito-Avo A, Simas C et al. Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon. Pediatr. Infect. Dis. J. 24, 243-252 (2005).
109. Stephens DS, Zughaier SM, Whitney CG et al., the Georgia Emerging Infections Program. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365, 855-863 (2005).
110. Bogaert D, Veenhoven RH, Sluijter M et al. Molecular epidemiology of pneumococcal colonization in response to pneumococcal conjugate vaccination in children with recurrent acute otitis media. J. Clin. Microbiol. 43, 74-83 (2005).